Seladelpar

ALIMENTARY TRACT AND METABOLISM

Key facts

Seladelpar is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2024. DrugCentral lists 3 molecular targets, including PPARD, PPARA and PPARG. Recorded indications include Primary biliary cholangitis.

• Approval status: onp (first approved 2024 by the FDA).
• Molecular targets: PPARD, PPARA and PPARG (3 listed in DrugCentral).
• Indications: Primary biliary cholangitis.
• ATC code: A05AX07 (Other drugs for bile therapy).
• Molecular formula: C21H23F3O5S; molecular weight 444.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Primary biliary cholangitis

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Peroxisome proliferator-activated receptor delta	PPARD	agonist	EC50 8.64
Peroxisome proliferator-activated receptor alpha	PPARA	agonist	EC50 5.84
Peroxisome proliferator-activated receptor gamma	PPARG	agonist	EC50 5.77

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2024-08-14	FDA	—	Gilead Sciences Inc	Yes

ATC classification

ATC code	Therapeutic hierarchy
A05AX07	ALIMENTARY TRACT AND METABOLISM › BILE AND LIVER THERAPY › BILE THERAPY › Other drugs for bile therapy

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP2C9 · Informative PGx
• FDA label: CYP2C9 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Blood alkaline phosphatase increased	87.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Seladelpar is on its molecule page.

• Molecular formula: C₂₁H₂₃F₃O₅S
• Molecular weight: 444.47 g/mol
• CAS number: —
• InChIKey: JWHYSEDOYMYMNM-QGZVFWFLSA-N
• PubChem CID: 11236126

CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Seladelpar used for?

DrugCentral lists the following indications for Seladelpar: Primary biliary cholangitis.

How does Seladelpar work?

Its molecular targets in DrugCentral include PPARD (agonist), PPARA (agonist) and PPARG (agonist).

When was Seladelpar first approved?

Seladelpar was first approved by the FDA in 2024.

What is the chemical formula of Seladelpar?

Seladelpar has the molecular formula C21H23F3O5S and a molecular weight of 444.47 g/mol.

Sources

• DrugCentral drug card 5830 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL230158 — compound record and bioactivity
• PubChem CID 11236126 — chemical identifiers
• DrugBank DB12390 — drug record
• FDA UNII 7C00L34NB9 — substance identity
• DailyMed: FDA labels for Seladelpar — current prescribing information (label search)
• UniProt Q03181 (PPARD) — target protein
• UniProt Q07869 (PPARA) — target protein
• UniProt P37231 (PPARG) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.